HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area purity target with related-substance reporting on request.
PeptiOEM · Catalog · Tirzepatide
GLP-1 family · Engine 2 (OUS only)
Tirzepatide OEM supply.
OUS markets & research only.
Lyophilized tirzepatide for OUS (non-US) distribution markets, research labs, and private-label brand evaluation outside the United States. 99%+ HPLC purity, per-batch COA + MS.
!
OUS & research only — not for US compounding under FDA 2026 proposal
On 2026-04-30 the FDA proposed removing GLP-1 medications from the 503B bulks list. Pending finalization, tirzepatide cannot be compounded from bulk substances by US 503B outsourcing facilities. PeptiOEM positions tirzepatide for OUS distribution and research only. Read the GLP-1 2026 update →
Lot TIR-10HPLC ≥ 99%MS confirmed5 / 10 / 15 / 30 mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Tirzepatide |
|---|---|
| Class | Dual GIP / GLP-1 receptor agonist (research) |
| Molecular weight | ≈ 4813.5 g/mol |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5 mg, 10 mg, 15 mg, 30 mg |
| Documentation | COA + HPLC + MS, per-batch lot file |
| Distribution scope | OUS markets & research only |
| Storage | 2–8 °C protected from light; long-term −20 °C |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat (OUS) | 2,000+ vials | 21–28 days, scheduled |
All tirzepatide quotes require a destination country and buyer track. Inquiries from US compounding facilities are answered with the 503B bulks list proposal and routed to non-GLP-1 alternatives.
Documentation
Per-batch document pack on every tirzepatide lot.
COA, HPLC chromatogram, MS identity, water content, and lot file. Distribution scope is confirmed before invoicing — we do not ship into restricted use cases.
MS identity
Mass spectrometry identity confirmation against the tirzepatide reference profile.
Destination check
Buyer track and destination country reviewed against the FDA 2026 503B bulks proposal before quoting.
FAQ
Tirzepatide — frequently asked by B2B buyers.
Why is tirzepatide marked OUS-only on this site?
On 2026-04-30 the FDA proposed removing GLP-1 medications from the 503B bulks list. If finalized, US 503B outsourcing facilities cannot compound tirzepatide from bulk substances. PeptiOEM positions tirzepatide for OUS (non-US) distribution markets, research, and private-label brand evaluation rather than US compounding.
Which markets do you serve for tirzepatide?
Latin America, Southeast Asia, parts of the Middle East, and select EMEA distributors with appropriate local registration. Buyer track and destination are confirmed before quoting.
Can research labs source tirzepatide?
Yes — lyophilized tirzepatide is supplied for laboratory research with COA, HPLC, and MS. US-bound research inquiries are reviewed against current FDA guidance and the 2026 503B bulks proposal.
What is the MOQ for OEM tirzepatide brand evaluation?
Sample lots from 100 vials; production lots from 500 vials. OEM-branded packaging (vial label, carton, document pack) is scheduled in 2,000-vial batches.
What does your COA report?
HPLC purity (target ≥99%), MS identity, water content, related-substance profile on request, and lot traceability tied to the document pack.
Related compounds